Futures Directions
Some other questions remain unanswered. In particular, although time-varying insomnia symptoms were taken into account in the current study, it is not possible to assess whether individuals showing a waxing and waning pattern of insomnia were at a similar risk of developing HF to those with chronic insomnia. Moreover, to the best of our knowledge, no studies have assessed the impact of daytime impairments, although these are part of the insomnia definition according to both the International Classification of Sleep Disorders (ICSD-3; AASM 2014) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V). Finally, yet importantly, does the treatment of insomnia symptoms reduce cardiovascular risk and HF incidence? The next step is probably to assess whether insomnia treatments such as cognitive behavioural therapy (CBT-I) reduce HF incidence.
Eur Heart J. 2021;42(40):4177-4179. © 2021 Oxford University Press
Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.
